AIM ImmunoTech Announces Stock Dividend

Rhea-AI Summary

AIM ImmunoTech (NYSE American: AIM) announced a stock dividend of one share for every 1,000 shares of common stock and one share for every outstanding option or warrant entitled to stock dividends.

Record date: January 9, 2026. Distribution/allocation to DTCC: January 13, 2026. Fractional shares will be rounded down; remaining fractional entitlements will be paid in cash based on a per‑share price of $1.305 (average high/low on December 29, 2025). Stockholders need take no action; additional shares will be credited to book‑entry accounts or delivered to brokers. The dividend is administered by EQ, the company's transfer agent.

OCALA, Fla., Dec. 30, 2025 (GLOBE NEWSWIRE) --  AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced a stock dividend of one share of common stock for every 1,000 shares of outstanding common stock as well as one share of common stock for every outstanding option or warrant that has a right to receive stock dividends (“Alternate Securities”). The dividend will be issuable to stockholders and Alternate Securities holders of record at the close of business on January 9, 2026 and will be distributed and allocated to DTCC on January 13, 2026.

Resulting fractional shares will be rounded down and any resulting fractional shares remaining after the foregoing rounding down will be distributed cash to each stockholder and Alternate Securities holder who would otherwise have been entitled to receive such fractional shares, based on a share price of $1.305, which is the average of the high and low share price on December 29, 2025.

Stockholders will not be required to take any action to receive the stock dividend. After the payment date, stockholders' book entry accounts will be credited with the additional shares that represent the stock dividend. Where shares are held in a brokerage account in the name of a broker, the additional shares will be distributed to the broker on the stockholder's behalf. The stock dividend is administered by EQ, the Company's transfer agent.

About AIM ImmunoTech Inc.

AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s lead product is a first-in-class investigational drug called Ampligen^® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system.

For more information, please visit aimimmuno.com and connect with the Company on X, LinkedIn, and Facebook.

Cautionary Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”). Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “continue,” “believe,” “potential,” “upcoming” and other variations thereon and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking statements. Many of these forward-looking statements involve a number of risks and uncertainties. Data, pre-clinical success and clinical success seen to date do not guarantee that Ampligen will be approved as a therapy for any indication. The Company urges investors to consider specifically the various risk factors identified in its most recent Form 10-K, and any risk factors or cautionary statements included in any subsequent Form 10-Q or Form 8-K, filed with the U.S. Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Among other things, for those statements, the Company claims the protection of the safe harbor for forward-looking statements contained in the PSLRA. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof.

Investor Contact:

JTC Team, LLC
Jenene Thomas
908.824.0775
AIM@jtcir.com

FAQ

What is the AIM (NYSE: AIM) stock dividend ratio announced on December 30, 2025?

AIM declared a stock dividend of 1 share for every 1,000 shares and 1 share for every outstanding option or warrant entitled to dividends.

What are the AIM stock dividend record and distribution dates for the January 2026 dividend?

Record date is January 9, 2026 and the dividend will be distributed/allocated to DTCC on January 13, 2026.

How will AIM handle fractional shares from the 1:1,000 stock dividend?

Fractional shares will be rounded down and any remaining fractional entitlements will be paid in cash using a per‑share price of $1.305.

Do AIM stockholders need to take any action to receive the January 2026 stock dividend?

No action is required; stockholders of record will automatically receive additional shares credited to their book‑entry accounts or delivered via their broker.

Will options or warrants receive the AIM stock dividend announced for January 2026?

Yes; the dividend applies to Alternate Securities, meaning options and warrants that have a right to receive stock dividends will receive the same 1:1,000 treatment.

Who administers the AIM stock dividend and where will allocated shares be sent?

The dividend is administered by EQ (transfer agent) and allocated to DTCC for distribution.